Zentalis Pharmaceuticals Inc [ZNTL] stock prices are up 0.16% to $12.54 at the moment. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The ZNTL shares have gain 7.09% over the last week, with a monthly amount drifted -6.49%, and not seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Zentalis Pharmaceuticals Inc [NASDAQ: ZNTL] stock has seen the most recent analyst activity on November 08, 2023, when Wedbush downgraded its rating to a Neutral and also revised its price target to $12 from $38. Previously, Leerink Partners downgraded its rating to Market Perform on November 07, 2023, and kept the price target unchanged to $15. On July 12, 2022, Cowen initiated with a Outperform rating. Wells Fargo started tracking the stock assigning a Overweight rating and suggested a price target of $67 on April 06, 2022. Stifel started tracking with a Buy rating for this stock on September 30, 2021, and assigned it a price target of $84. In a note dated September 29, 2021, Oppenheimer initiated an Outperform rating and provided a target price of $90 on this stock.
The stock price of Zentalis Pharmaceuticals Inc [ZNTL] has been fluctuating between $9.56 and $31.46 over the past year. Currently, Wall Street analysts expect the stock to reach $40.67 within the next 12 months. Zentalis Pharmaceuticals Inc [NASDAQ: ZNTL] shares were valued at $12.54 at the most recent close of the market. An investor can expect a potential return of 224.32% based on the average ZNTL price forecast.
Analyzing the ZNTL fundamentals
Gross Profit Margin for this corporation currently stands at 0.97% with Operating Profit Margin at -6.08%, Pretax Profit Margin comes in at -4.83%, and Net Profit Margin reading is -5.13%. To continue investigating profitability, this company’s Return on Assets is posted at -0.39, Equity is -0.46 and Total Capital is -0.52. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.1.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 11.97 points at the first support level, and at 11.39 for the second support level. However, for the 1st resistance point, the stock is sitting at 12.93, and for the 2nd resistance point, it is at 13.31.
Zentalis Pharmaceuticals Inc [ZNTL] reported earnings per share of $0.14 for its fiscal quarter that ended on 3/31/2024. Based on the Wall Street analysts’ estimates, the company was expected to report earnings of -$0.77/share, meaning a difference of $0.91 and a surprise factor of 118.20%. By comparison, the stated earnings for the previous quarter ended on 12/31/2023 were -$0.93 per share as compared to estimates of -$0.92 per share, a difference of -$0.01 representing a surprise of -1.10%.
Ratios To Look Out For
It’s worth pointing out that Zentalis Pharmaceuticals Inc [NASDAQ:ZNTL]’s Current Ratio is 9.19. Also, the Quick Ratio is 9.19, while the Cash Ratio stands at 0.69. Considering the valuation of this stock, the price to sales ratio is 21.95, the price to book ratio is 1.94.
Transactions by insiders
Recent insider trading involved HAUSMAN DIANA, Chief Medical Officer, that happened on May 09 ’24 when 3356.0 shares were sold. Chief Financial Officer, Epperly Melissa B, completed a deal on Feb 12 ’24 to sell 2573.0 shares. Meanwhile, President Gallagher Cam sold 1173.0 shares on Feb 12 ’24.
